The proposed study is a placebo-controlled, add-on, randomized trial using parallel group designs. This is a close-label and adaptive, multi-centered design with 1:1 allocation ratio and superiority framework. It will be conducted in multiple designated corona centers established by the Government of Pakistan.
How understandable was the trial content above?
Hard to understand
Easy to understand
